FDA Commissioner, Scott Gottlieb, MD, has created a new FDA working group of senior agency staff who will investigate ways to increase generic drug competition.
FDA Commissioner, Scott Gottlieb, MD, has created a new FDA working group of senior agency staff who will investigate ways to increase generic drug competition.
The agency has already taken steps to address what Gottlieb calls “gaming” of the regulatory system by some drug makers who seek to delay the approval of generic drugs. Thus far, the agency has begun work on a Drug Competition Action Plan, held a public meeting on the administration of the Hatch-Waxman Amendments, published a list of off-patent branded drugs that do not yet have approved generics, announced upcoming publication of 2 new documents designed to help generics companies navigate the Abbreviated New Drug Application process, and announced a new policy to expedite the review of generic drug applications.
The new initiative, Gottlieb said on Twitter, will expand upon the goals of the agency’s Action Plan:
The working group will also develop proposals to address ongoing difficulties in administering the Hatch-Waxman Amendments:
Yet the new initiative also seeks to move beyond those current efforts, and to identify new ideas and approaches that will improve access to generic drugs:
BioCentury reports that the working group’s membership includes Elizabeth Dickinson, JD, an FDA attorney in the Office of the Chief Counsel; Grail Sipes, JD, director of the Office of Regulatory Policy at the agency’s Center for Drug Evaluation and Research (CDER), and Maryll Toufanian, JD, deputy director of CDER’s Office of Generic Drug Policy.
The formation of the new working group follows Gottlieb’s recent congressional testimony, during which he highlighted barriers to competition in the pharmaceuticals marketplace. Among the barriers Gottlieb identified were restricted distribution systems and access to drugs for bioequivalence testing; single, shared systems for risk evaluation and mitigation strategies (REMS); citizen petitions, drugs not yet addressed under the 2006 Unapproved Drugs Initiative; and so-called “pay-for-delay” agreements, in which generics companies resolve patent disputes by agreeing to delay market entry in exchange for a sum of money.
Since his confirmation as FDA Commissioner in May, Gottlieb has made drug pricing a focus of the agency’s attention, and the formation of the working group suggests that these efforts to increase competition and drive down drug costs will only continue.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.